Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Armando Genazzani"'
Autor:
Mario Paolo Colombo, Cristina Travelli, Giorgia Colombo, Sabina Sangaletti, Armando Genazzani
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/55a29c04e07140b9b211431a73f5aa35
Autor:
Claudio Jommi, Elisabetta Listorti, Federico Villa, Simone Ghislandi, Armando Genazzani, Agnese Cangini, Francesco Trotta
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-10 (2021)
Abstract Background and aim Evidence on determinants of prices for orphan medicines is scarce and not available for Italy. The aim of this paper is to provide an evidence on variables affecting the annual treatment cost of orphan drugs in Italy, test
Externí odkaz:
https://doaj.org/article/3b1356b07d8a4883a3a451e4cc588b24
Autor:
Federico Villa, Aurora Di Filippo, Andrea Pierantozzi, Armando Genazzani, Antonio Addis, Gianluca Trifirò, Agnese Cangini, Giovanni Tafuri, Daniela Settesoldi, Francesco Trotta
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionIt is well acknowledged that the price of orphan drugs is normally higher than that resulting from the value-based pricing. A correlation between the cost of therapy for orphan drugs and the epidemiology (prevalence and incidence) of the
Externí odkaz:
https://doaj.org/article/afb495ca257e4a7d93148e83fe67162f
Autor:
Annamaria Antona, Marco Varalda, Konkonika Roy, Francesco Favero, Eleonora Mazzucco, Miriam Zuccalà, Giovanni Leo, Giulia Soggia, Valentina Bettio, Martina Tosi, Miriam Gaggianesi, Beatrice Riva, Simone Reano, Armando Genazzani, Marcello Manfredi, Giorgio Stassi, Davide Corà, Sandra D’Alfonso, Daniela Capello
Publikováno v:
Cancers, Vol 14, Iss 3, p 776 (2022)
Approximately 50% of colorectal cancer (CRC) patients still die from recurrence and metastatic disease, highlighting the need for novel therapeutic strategies. Drug repurposing is attracting increasing attention because, compared to traditional de no
Externí odkaz:
https://doaj.org/article/dab999ddb7914de99929d8bc054414da
Autor:
Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Mario Alberto Clerico, Pierfranco Conte, Filippo de Braud, Francesco De Lorenzo, Maria Gabriella Ferrandina, Armando Genazzani, Stefania Gori, Michele Maio, Mauro Patroncini, Francesco Perrone, Giovanni Scambia, Giovanna Scroccaro
Publikováno v:
Global & Regional Health Technology Assessment, Vol 2019 (2019)
Timely access to cancer therapies with significant added value is an important expectation for patients and a primary responsibility for every public health service. Over time, collaboration between the pharmaceutical industry and regulatory agencies
Externí odkaz:
https://doaj.org/article/c5019046ec194786959745e25f17f775
Autor:
Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Mario Alberto Clerico, Pierfranco Conte, Filippo de Braud, Francesco De Lorenzo, Maria Gabriella Ferrandina, Armando Genazzani, Stefania Gori, Michele Maio, Mauro Patroncini, Francesco Perrone, Giovanni Scambia, Giovanna Scroccaro
Publikováno v:
Global & Regional Health Technology Assessment, Vol 6, Iss 1 (2019)
Externí odkaz:
https://doaj.org/article/ff32ed0d3bca45cda0448bdbec60ca2f
Autor:
Federico Villa, Claudio Jommi, Armando Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini
Publikováno v:
Global & Regional Health Technology Assessment, Vol 2018 (2018)
The European Medicines Agency (EMA) has adopted assessment systems and drug registration procedures to respond to the needs for rapid patient access to therapies, such as Conditional Marketing Approval (CMA) and Under Exceptional Circumstances approv
Externí odkaz:
https://doaj.org/article/50aa302b9b3740eb97e248fe576f99f4
Autor:
Federico Villa, Claudio Jommi, Armando Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini
Publikováno v:
Global & Regional Health Technology Assessment, Vol 5, Iss 1 (2018)
Externí odkaz:
https://doaj.org/article/1755aadf55444faf852a61e27a92575f
Autor:
Paola Marmiroli, Beatrice Riva, Eleonora Pozzi, Elisa Ballarini, Dmitry Lim, Alessia Chiorazzi, Cristina Meregalli, Carla Distasi, Cynthia L Renn, Sara Semperboni, Lavinia Morosi, Federico A Ruffinatti, Massimo Zucchetti, Susan G Dorsey, Guido Cavaletti, Armando Genazzani, Valentina A Carozzi
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0186250 (2017)
Peripheral neurotoxicity is one of the most distressing side effects of oxaliplatin therapy for cancer. Indeed, most patients that received oxaliplatin experience acute and/or chronic severe sensory peripheral neuropathy. However, despite similar co-
Externí odkaz:
https://doaj.org/article/ca07749fff9841d68f95245bfbc6aef8
Autor:
Giovanni Barosi, Alberto Bosi, Maria P. Abbracchio, Romano Danesi, Armando Genazzani, Paolo Corradini, Fabrizio Pane, Sante Tura
Publikováno v:
Haematologica, Vol 96, Iss 7 (2011)
Externí odkaz:
https://doaj.org/article/86905d0572354468b7fccaac014ad480